DGAP-News

Novavax to Present at the 2013 Stifel Nicolaus Healthcare Conference

Novavax, Inc.

05.09.2013 14:30
---------------------------------------------------------------------------

ROCKVILLE, Md., 2013-09-05 14:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today
that Stanley C. Erck, President and Chief Executive Officer, will present at
the 2013 Stifel Nicolaus Healthcare Conference on Thursday, September 12, 2013
at 9:45 a.m. ET in Boston, MA at the Four Seasons.

A live webcast link for the presentation will be available at the company
website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines to address a broad range of infectious diseases
worldwide. Using innovative proprietary recombinant protein nanoparticle
vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases. Novavax is
involved in several international partnerships, including collaborations with
Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently
acquired Isconova AB, a leading vaccine adjuvant company located in Sweden.
Together, Novavax' network supports its global commercialization strategy to
create real and lasting change in the biopharmaceutical and vaccinology fields.
Additional information about Novavax is available on the company's website,
novavax.com.


CONTACT: Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX



05.09.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Novavax, Inc.


United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6700021040
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------